株探米国株
英語
エドガーで原本を確認する
6-K 1 tm248752d1_6k.htm FORM 6-K

 

 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

 

Pursuant to Rule 13a-16 or 15d-16 of the 

Securities Exchange Act of 1934 

For the month of March 2024

 

Commission file number: 001-32749

 

FRESENIUS MEDICAL CARE AG 

(Translation of registrant's name into English)

 

Else-Kröner Strasse 1 

61346 Bad Homburg 

Germany 

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F   x                   Form 40-F   ¨

 

 

 

 


 

EXHIBITS

 

The following exhibits are being furnished with this Report:

 

Exhibit 99.1 Press Release issued on March 13, 2024

 

 


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

DATE: March 13, 2024

 

  Fresenius Medical Care AG

 

  By: /s/ Helen Giza
  Name: Helen Giza
  Title: Chief Executive Officer and Chair of the Management Board

 

  By: /s/ Martin Fischer
  Name: Martin Fischer
  Title: Chief Financial Officer and member of the Management Board

 

 

 

EX-99.1 2 tm248752d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

 

Press Release

Media contact 

Christine Peters 

T +49 160 60 66 770
christine.peters@freseniusmedicalcare.com

 

Contact for analysts and investors 

Dr. Dominik Heger 

T +49 6172 609 2601
dominik.heger@freseniusmedicalcare.com

 

www.freseniusmedicalcare.com

 

Fresenius Medical Care appoints Jörg Häring as new Management Board member responsible for Legal, Compliance and Human Resources

 

· Effective June 1, the Legal, Compliance, and Human Resources functions will be combined in a new Management Board role
     
· Jörg Häring contributes his extensive expertise from the energy, industry, and healthcare sectors

 

Bad Homburg (March 13, 2024) Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, has announced today the appointment of Jörg Häring (54) as its new Global Head of Legal, Compliance and Human Resources. Häring, who will join the company as a member of the Management Board, will start on June 1, 2024, and also assume the role of Labor Director.

 

Michael Sen, Chairman of the Supervisory Board of Fresenius Medical Care AG, said: “We are delighted to welcome Jörg Häring to the Management Board of Fresenius Medical Care. With his international experience and expertise in corporate governance and legal matters, he perfectly adds to the existing Management Board team. With his proven track record of successful growth and transformation projects at multinational companies he will play a crucial role in the company’s further turnaround.”

 

Jörg Häring is currently a member of the Management Committee, Chief Legal & Assurance Officer, and General Secretary at the Spanish oil company Compañía Española de Petróleos (CEPSA), with global responsibility for Legal, Corporate Audit, Risk, and Compliance. Previously, he spent more than 20 years with the Siemens Group, among others as General Counsel for almost 13 years, with a wide range of regional and industry responsibilities. Häring brings excellent knowledge and a broad experience in Corporate Governance.

 

Page 1/2


 

Prior to joining Siemens in 2002, Häring worked at the law firm Cleary, Gottlieb, Steen & Hamilton, based in Frankfurt and Brussels. He holds a PhD in law and a degree in economics from the University of Tübingen (Germany) and has been admitted lawyer to the bar by Munich District Court II.

 

Helen Giza, CEO and Chair of the Management Board of Fresenius Medical Care AG, said: “Jörg joins Fresenius Medical Care with more than two decades of career experience as a senior legal executive and corporate leader in the energy and healthcare sectors. He combines strong business knowledge with great functional expertise, people skills and a focus on corporate culture. He will support our cultural change with inspiration and determination. I look forward to working with him on our transformational journey.”

 

“It’s an honor and a privilege to become Head of Legal, Compliance and Human Resources at Fresenius Medical Care and to lead these functions and the people strategy to the next phase in the company’s transformation. I’m very proud to partner with the employees and leaders as we work to transform the organization to serve our employees, shareholders and further stakeholders,” said Jörg Häring.

 

About Fresenius Medical Care: 

Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 3.9 million patients worldwide regularly undergo dialysis treatment. Through its network of 4,000 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approximately 332,000 patients around the globe and is the leading provider of dialysis products such as dialysis machines and dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

 

For more information visit the Company’s website at www.freseniusmedicalcare.com.

 

Disclaimer: 

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts related to the COVID-19 pandemic results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care’s reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care does not undertake any responsibility to update the forward-looking statements in this release.

 

Page 2/2